Bullfrog AI Holdings (BFRG) Value Adjusted for Debt and Cash

Corporate company logo of Bullfrog AI Holdings, Inc. (BFRG)

The efficiency of Bullfrog AI Holdings (BFRG) relies on the accuracy of bfLEAP forecasts and the number of contracts with biotech firms, while the business minimizes environmental impact through its digital format. This chart illustrates the asset's market value at 1.98, serving as a development indicator. Bullfrog AI Holdings (BFRG) creates AI tools for processing medical data, strengthening its authority through the ability of its algorithms to reduce risks during the testing of new drugs.

BFRG bullfrogai.com: Enterprise Value in the range 11/23/2025 - 10/28/2026

Analytical breakdowns for Bullfrog AI Holdings

- price and consensus price forecast:
Quote Chart Bullfrog AI Holdings, Inc.|BFRG - Price Target Chart
- market capitalization data:
Market Value Bullfrog AI|BFRG - Enterprise Value
- book capitalization data:
Book Value of One Share Bullfrog AI|BFRG - Book Capitalization|Market Capitalization to Book Value bullfrogai.com|BFRG - Cumulative Company Assets
- debt and liquidity data:
Aggregate Debt to Capital Bullfrog AI Holdings|BFRG - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital Bullfrog AI Holdings, Inc.|BFRG - Company Debts|Debt to Book Value Bullfrog AI|BFRG - Company Long-Term Debts|Short-Term Debt Bullfrog AI
Fundamental company valuation:BFRG (Bullfrog AI Holdings)
Mass-produced product of Bullfrog AI Holdings Inc

An objective business valuation is critical for minimizing investment risks when selecting an issuer. Enterprise Value, calculated as the sum of market capitalization and debt minus cash, determines the actual buyout price of a company. By analyzing enterprise value dynamics, an investor can identify a smoothed trend devoid of speculative noise. The current value of 1.98 reflects the market weight of Bullfrog AI Holdings (BFRG). This allows for an assessment of the AI platform's capitalization in the context of its ability to optimize the cost of new drug development.

Direct competitors

Veeva Systems - Full Business Value|Total Company Value Doximity Corp (DOCS)|HQY - Value Adjusted for Debt and Cash|Enterprise Value WAY (Waystar Holding Corp.)|corvel.com (CRVL) - Full Takeover Company Value|PRVA: Enterprise Value|Company Buyout Price Huron Consulting Group Inc. (HURN)|Real Price to Acquire Entire Company Certara Corp|Aggregate Business Value Omnicell Health OMCL|Real Price to Acquire Entire Company GoodRx Holdings, Inc.|schrodinger.com - Value Adjusted for Debt and Cash|PHR: Total Company Value|OMDA - Real Price to Acquire Entire Company|Enterprise Value EVH|HealthStream Learning (HSTM) - Total Enterprise Value|Enterprise Value Definitive Healthcare (DH)|Business Value consensus.com|Enterprise Value agilon health (AGL)|Total Company Value Absci Corp ABSI|Real Price to Acquire Entire Company SY (SoYoung)|NRC Health - Enterprise Value|SPOK - Total Company Value|OPRX: Total Company Value|TruBridge (TBRG) - Total Company Value|Simulations Plus Inc (SLP) - Total Company Value|Enterprise Value Sophia Genetics SOPH|Full Business Value HCAT|CareCloud, Inc. (CCLD) - Total Company Value|Value Adjusted for Debt and Cash RSSS (Research Solutions Inc.)|DLHC: Total Company Value|Total Enterprise Value OneMedNet Corp ONMD|Enterprise Value SCNX|Healthcare Triangle Corporation (HCTI) - Full Takeover Company Value|Real Price to Acquire Entire Company ispecimen.com ISPC|scworx.com (WORX) - Value Adjusted for Debt and Cash|MSPR (MSP Recovery) - Enterprise Value|Enterprise Value iCoreConnect Corp|MEDS (TRxADE) - Enterprise Value|Company Buyout Price Orgenesis Corporation ORGS|Real Price to Acquire Entire Company R1 RCM|Value Adjusted for Debt and Cash sharecare.com SHCR|Enterprise Value Streamline Health (STRM)|SYRA: Value Adjusted for Debt and Cash|Total Company Value AMEH|MODN (Model N Corporation) - Total Enterprise Value|Total Company Value NextGen Healthcare